Wolff-Parkinson-White syndrome is a relatively common preexcitation syndrome which has appeared multiple times in the Second Part CICM exam. Its appearances are usually of the same basic format. The trainees are usually posed with an ECG which bears a characteristic delta wave, and then asked to comment on the management of a tachyarrhythmia. The ECG interpretation is usually worth very few marks, because it is a boring exercise in pattern recognition for a very obvious pattern. The real test of character is in the decisionmaking around antiarrhythmic choice, when trying to address an acute SVT in these patients. As should become apparent from the discussion below, this is far from straightforward, as there does not appear to be any consistency in expert recommendations for best practice, nor in the college examiner comments.

Historical appearances of WPW in the exam include the following:

Specific issues asked about have included the characteristic ECG findings (short PR and delta waves), contraindicated drugs (AV nodal blockers like digoxin), and complications (SVT and sudden cardiac death). In brief, that's all you need to know. But of course many people (among them college examiners) would not be satisfied with a single sentence answer.  To address the issues of WPW in greater detail, one may need to refer to published literature. If one were pressed for time, one may safely limit one's reading to the LITFL page on WPW. If one were for some reason in need of greater detail, one might instead read the  UpToDate chapter on WPW.

Pathophysiology and ECG features of WPW

WPW is characterised by the presence of the Bundle of Kent, an accessory conducting pathway which is closer to the SA node than the AV node is. The atria are well-behaved, and they politely conduct the impulse from the SA node along the usual fast conduits. The P wave, therefore, is normal in appearance. Then, the impulse reaches the Bundle of Kent, and it conducts the impulse first, before the AV node has a chance.

The result is a short AV conduction time, and an abnormal pattern of depolarisation, with some of the ventricular mass depolarising some milliseconds before the rest. Electrophysiology findings are diagnostic, but one does not need EPS to make the diagnosis (SVT and characteristic sinus ECG findings seem to be enough). Thus, the ECG features of WPS are:

  • The PR interval is short (less than 0.12 seconds)
  • There is a delta wave (a slurred upstroke of the QRS complex)
  • Wide QRS (because the delta wave widens it)
  • ST Segment and T wave discordant changes: T waves point in the opposite direction to the QRS.
  • Pseudo-Q waves: negatively deflected delta waves in the inferior / anterior leads
  • prominent R wave in V1-3 (mimicking posterior infarction).

Ideally, this sort of ECG should come with a history of syncopal episodes.

Complications of WPW

What could go wrong:

  • SVT, which comes in two flavours. if the complexes are narrow, its orthodromic. If they are wide and with delta-waves, its antidromic. Does that really matter? Turns out, yes. Orthodromic SVT in WPW can be treated much like any other SVT (adenosine, vagal manoeuvres etc), whereas in antidromic SVT many of the usual drugs are contraindicated.
  • AF  is disturbingly common in WPW- 10 to 30% of patients will have it at some point. Question 26.1 from the first paper of 2016  demonstrates what this looks like:

    • Having AVRT predisposes one to AF in this situation because the reentry circuit via the accessory pathway can cause the atria to contract quite randomly (after all, the accessory pathway is not a serious part of the conducting system, and it doesn’t link into any sort of conduction pathways- its just going to excite any old patch of atrium). The ECG will throw you off. The conduction rate is roughly 1:1.5; the QRS rate is about 180 to 200. It is hard to tell that its irregularly irregular. The QRS complexes will be a mixture of pre-excited delta-waving ones, and normal-looking narrow ones. If the accessory pathway has a short refractory period, it will conduct more often and therefore there will be more broad complexes than narrow ones. The shorter the refractory period of the accessory pathway, the broader the QRS. And the broader the QRS, the greater the chance of this thing degenerating into ventricular fibrillation.
  • Atrial flutter can also conduct via the bundle of Kent. There will be 1:1 conduction. Ventricular rate will approach 300. Because this is an antidromic way of conducting impulses, the QRS complexes will be broad and there will be delta waves. Unlike AF, the rate runs with a metronome-like regularity. The patient will likely look dead.
  • Ventricular fibrillation is a common cause of sudden cardiac death among the WPWs. So, in AF with WPW conduction, the rate of ventricular contraction is increased, and the regularity is decreased. This fractionates the wavefront of ventricular depolarization. Soon enough, there are numerous wavefronts all moving around the ventricle. This is ventricular fibrillation. If you block the AV node, occasionally the accessory pathway will launch the ventricles into this. It’s a known, and extremely uncommon, complication of adenosine use in WPW.
  • Syncope and sudden cardiac death are the natural histories of these arrhythmias in WPW, because they are frequently too fast to be perfusing rhythms. The surviving sufferer is typically saved by their youth, as they may be better able to tolerate hummingbird-like heart rate for sustained periods.

Antiarrhythmic choice for acute management of SVT in WPW

Why is this even a thing? Consider: WPW is a preexcitation syndrome where an accessory conduction pathway bypasses the AV node and directly depolarises a little patch of the ventricle. Fortunately, the AV node has the advantage of being connected to the His bundle, which rapidly conducts the action potential to all four corners of the heart.  The accessory pathway is therefore unable to do any real harm because the tissue depolarised by the accessory pathway is soon surrounded on all sides by recently depolarised ventricular muscle, and the refractory periods of those cells limit the propagation of this rebel action potential.

Orthodromic SVT in WPW

In orthodromic SVT, the action potential enters the AV node, propagates down the bundle of His, depolarises the ventricles, reenters the atria via the accessory pathway, and stimulates the AV node again. As in any normal SVT, this is something that should respond well to AV nodal blockers. If you block the AV node, the reentry of the action potential will only stimulate the atria and then dissipate harmlessly against the blocked node, and propagate no further. That ends the cycle, as there will be no ventricular action potential to reenter and stimulate the atria, which means that the next pulse should be a good honest sinus beat. On the basis of this, the UpToDate boffins recommend standard anti-SVT pharmacotherapy:

"The approach to patients with orthodromic AVRT is similar to patients with other types of paroxysmal supraventricular tachycardia... AV nodal blocking agent (ie, adenosine, verapamil, beta blockers) should be instituted. We suggest intravenous adenosine rather than intravenous verapamil as the initial choice based on its efficacy and short half-life. "

Antidromic SVT in WPW

In antidromic SVT, the action potential conducts to the ventricle initially via the accessory pathway, then wanders shambolically around the ventricles producing a weird wide QRS, and then propagates up the AV node in an unnatural retrograde manner. It then goes straight back down into the ventricle via the accessory pathway, and the whole thing repeats cyclically. 

So, consider what might happen if the AV node were blocked. The ventricle is now only depolarised by the accessory pathway, so the QRS will be weird and wide, but now that the AV node is blocked, theoretically the block should have the exact same effect as in orthodromic SVT, i.e. the cycle is broken and the SVT should be aborted. 

However, the authorities are not convinced. UpToDate hold forth that:

"Even though retrograde AV node conduction may be a "weak link" during antidromic AVRT, intravenously administered AV node-specific blocking drugs such as adenosine, verapamil, and beta blockers should be avoided unless the tachycardia is definitely known to be antidromic AVRT.  ...If the diagnosis is not certain, the patient should be considered to have an undiagnosed wide QRS tachycardia"

Interpreting this literally, it would appear that they would also recommend AV blockers for antidromic SVT, just as they would for orthodromic SVT, just as long as you are absolutely sure that it is antidromic. Or orthodromic. In short, either version of SVT in WPW seem to be theoretically susceptible to the safe use of AV nodal blockers, but if the QRS complexes are broad, you should not assume that it is antidromic SVT, but rather consider the possibility that it is either AF with WPW or a proper ventricular tachycardia. 

Which brings us to...


Atrial fibrillation in WPW is a hideous thing. The erratic atrial action potentials getting propagated down the accessory pathway are a source of bizarre broad QRS complexes which bounce crazily around the ventricle and create an electrical environment richly conducive to early afterdepolarisations. These are hopefully balanced by some normal narrow-complex action potentials propagating down the AV node, which should depolarise the ventricle in a more organised fashion, hopefully preventing any ventriculofibrillatory shenanigans by putting enough of the ventricle into an absolute refractory period. In the bloodshot light of the pre-dawn ICU shift, the ECG picture (particularly if the narrow complexes are outnumbered) may look like the broad-QRS appearance of an antidromic SVT.

Now, consider using an AV blocker in this scenario. The AV node no longer conducts any normal potentials, and ventricular activity is being driven solely by the total chaos of the fibrillating atria. The ventricular rate is no longer limited by the stabilising apperance of "properly" conducted beats, and the ventricle ends up stimulated by a cacophony of action potentials arriving at some rate between 300-600 per minute. The effect is illustrated by the image below, which was shamelessly stolen from Shah (2011) via  this excellent blog:

WPW AF turning into VF following adenosine

Note that adenosine is not required for this. WPW AF is perfectly capable of degenerating into VF all on its own, as demonstrated here in a rhythm strip from the MSD Manual:

WPW AF turning into VF all on its own

Safe practice in SVT with WPW

So, in summary, what can we safely say about the management of acute SVT in WPW? 

  • Theoretically, AV nodal blockers should be safe in WPW-associated SVT, be it antidromic or orthodromic. If one thinks for a minute about the epidemiology of SVT, one will come to the conclusion that a large proportion of SVT is in fact caused by WPW or some other sort of preexcitaton syndrome, which is usually not known at the time of their first presentation. Many of these people get adenosine, which then reveals their delta waves to the horrified emergency personnel. Most of them do not die of VF. On the basis of this, we may conclude that it is probably reasonably safe.
  • Practically, antidromic SVT in WPW may be difficult to discriminate from AF or VT. Broad complexes and 300+ heart rates could be anything in WPW. Sure, it could be supraventricular, and respond to adenosine. Or it could be AF, and turn into VF. Or it could be VT, which will not benefit from an AV nodal blocker, in which case you have wasted precious time.

On this basis, the authorities tend to recommend the use of Class I or Class III agents instead of AV nodal blockers. The model answer to Question 3.1 from the first paper of 2009 lists procainamide and amiodarone as first-line agents, whereas digoxin and verapamil are contraindicated. Digoxin decreases the refractory period of the accessory pathway and verapimil tends to accelerate the ventricular response to AF by a similar mechanism. Since 2009, public opinion has also drifted away from amiodarone. As an acute infusion it is basically a beta-blocker with some AV nodal specificity. It is therefore the wrong drug for acute management of WPW SVT; or rather, it will probably be safe in the narrow-complex-obviously-orthodromic population, with the aforementioned caveats. In the long term, it becomes more useful, as its Class III and Class I effects begin to develop, slowing conduction down the accessory pathway.

 The table below has been compiled with the use of the belowlisted references and the UpToDate article on this topic

Pharmacological Peculiarities of WPW
Arrhythmia Drugs contraindicated Drugs Recommended
Orthodromic AVRT  
  • Adenosine
  • Verapamil
  • Diltiazem
  • Procainamide
  • Amiodarone
Antidromic AVRT
  • Adenosine
  • Verapamil
  • Diltiazem
  • β-blockers
  • Digoxin
  • Procainamide
  • Flecainide
  • Propafenone
  • Amiodarone
  • Adenosine
  • Verapamil
  • Diltiazem
  • ß-blockers
  • Digoxin
  • Procainamide
  • Ibutilide
  • Dofelitide
  • Flecainide
  • Amiodarone



Wellens, Hein JJ, and Dirk Durrer. "Effect of digitalis on atrioventricular conduction and circus-movement tachycardias in patients with Wolff-Parkinson-White syndrome." Professor Hein JJ Wellens. Springer Netherlands, 2000. 63-68.

Gulamhusein, S. A. J. A. D., et al. "Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil."Circulation 65.2 (1982): 348-354.

Munger, T. M., et al. "A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989."Circulation 87.3 (1993): 866-873.

Svenson, ROBERT H., et al. "Electrophysiological evaluation of the Wolff-Parkinson-White syndrome: problems in assessing antegrade and retrograde conduction over the accessory pathway." Circulation 52.4 (1975): 552-562.

Narula, Onkar S. "Wolff-Parkinson-White Syndrome A Review." Circulation 47.4 (1973): 872-887.

and, somewhat more recently...

Scheinman, Melvin M. "History of Wolff‐Parkinson‐White Syndrome." Pacing and clinical electrophysiology 28.2 (2005): 152-156.

Keating, L., F. P. Morris, and W. J. Brady. "Electrocardiographic features of Wolff-Parkinson-White syndrome." Emergency medicine journal 20.5 (2003): 491-493.

Luigi Di Biase, M. D., Edward P. Walsh, and Bradley P. Knight. "Treatment of symptomatic arrhythmias associated with the Wolff-Parkinson-White syndrome." UpToDate
Shah, C. P., et al. "Adenosine-induced ventricular fibrillation." Indian heart journal 53.2 (2001): 208-210.